Protein kinase inhibitors for acute leukemia

Conventional treatments for acute leukemia include chemotherapy, radiation therapy, and intensive combined treatments (including bone marrow transplant or stem cell transplants). Novel treatment approaches are in active development. Recently, protein kinase inhibitors are on clinical trials and offe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ling, Yuan, Xie, Qing, Zhang, Zikang, Zhang, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809833/
https://www.ncbi.nlm.nih.gov/pubmed/29456860
http://dx.doi.org/10.1186/s40364-018-0123-1
_version_ 1783299623449788416
author Ling, Yuan
Xie, Qing
Zhang, Zikang
Zhang, Hua
author_facet Ling, Yuan
Xie, Qing
Zhang, Zikang
Zhang, Hua
author_sort Ling, Yuan
collection PubMed
description Conventional treatments for acute leukemia include chemotherapy, radiation therapy, and intensive combined treatments (including bone marrow transplant or stem cell transplants). Novel treatment approaches are in active development. Recently, protein kinase inhibitors are on clinical trials and offer hope as new drugs for acute leukemia treatment. This review will provide a brief summary of the protein kinase inhibitors in clinical applications for acute leukemia treatment.
format Online
Article
Text
id pubmed-5809833
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58098332018-02-16 Protein kinase inhibitors for acute leukemia Ling, Yuan Xie, Qing Zhang, Zikang Zhang, Hua Biomark Res Review Conventional treatments for acute leukemia include chemotherapy, radiation therapy, and intensive combined treatments (including bone marrow transplant or stem cell transplants). Novel treatment approaches are in active development. Recently, protein kinase inhibitors are on clinical trials and offer hope as new drugs for acute leukemia treatment. This review will provide a brief summary of the protein kinase inhibitors in clinical applications for acute leukemia treatment. BioMed Central 2018-02-13 /pmc/articles/PMC5809833/ /pubmed/29456860 http://dx.doi.org/10.1186/s40364-018-0123-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Ling, Yuan
Xie, Qing
Zhang, Zikang
Zhang, Hua
Protein kinase inhibitors for acute leukemia
title Protein kinase inhibitors for acute leukemia
title_full Protein kinase inhibitors for acute leukemia
title_fullStr Protein kinase inhibitors for acute leukemia
title_full_unstemmed Protein kinase inhibitors for acute leukemia
title_short Protein kinase inhibitors for acute leukemia
title_sort protein kinase inhibitors for acute leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809833/
https://www.ncbi.nlm.nih.gov/pubmed/29456860
http://dx.doi.org/10.1186/s40364-018-0123-1
work_keys_str_mv AT lingyuan proteinkinaseinhibitorsforacuteleukemia
AT xieqing proteinkinaseinhibitorsforacuteleukemia
AT zhangzikang proteinkinaseinhibitorsforacuteleukemia
AT zhanghua proteinkinaseinhibitorsforacuteleukemia

Ejemplares similares